Clinical Trials in Arizona

Showing 10281-10300 of 14,395 trials

Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer

NCT00009945

RATIONALE: Clodronate may be effective in preventing the spread of cancer to the bones and other parts of the body. It is not yet known whether clodronate is more effective alone or combined with chemotherapy and /or hormonal therapy in preventing metastatic breast cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of clodronate with or without chemotherapy and /or hormonal therapy in preventing metastases in women who have stage I or stage II breast cancer.

Breast Cancer

NSABP Foundation Inc3,323 participantsStarted Jan 2001

Scottsdale, Arizona, United States • Jacksonville, Florida, United States • Honolulu, Hawaii, United States +14 more locations

COMPLETEDPhase 1/231 miles

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

NCT01057225

RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells by blocking blood flow to the tumor. Giving combination chemotherapy together with carfilzomib and thalidomide may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of carfilzomib when given together with cyclophosphamide, thalidomide, and dexamethasone in treating patients with newly diagnosed active multiple myeloma.

Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more

Mayo Clinic64 participantsStarted Mar 2010

Scottsdale, Arizona, United States • Rochester, Minnesota, United States • Charleston, South Carolina, United States

Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

Find Trials by Condition in Arizona

A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis

Safety and Efficacy Trial of Testosterone Undecanoate

Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older

Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes

OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females

Evaluation of the Ulthera System for the Treatment of the Decolletage

Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation

An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

A Study of Vemurafenib in Participants With Metastatic Melanoma

HOPE Demonstration Field Experiment Multisite Evaluation

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)